116 related articles for article (PubMed ID: 33578097)
1. Chronic nickel (II) exposure induces the stemness properties of cancer cells through repressing isocitrate dehydrogenase (IDH1).
Wang L; He S; Xiong Z; Lu J; Lin Y; Jin H; Yang L
Ecotoxicol Environ Saf; 2021 Apr; 213():112031. PubMed ID: 33578097
[TBL] [Abstract][Full Text] [Related]
2. R132H mutation in IDH1 gene reduces proliferation, cell survival and invasion of human glioma by downregulating Wnt/β-catenin signaling.
Cui D; Ren J; Shi J; Feng L; Wang K; Zeng T; Jin Y; Gao L
Int J Biochem Cell Biol; 2016 Apr; 73():72-81. PubMed ID: 26860959
[TBL] [Abstract][Full Text] [Related]
3. Nickel-induced HIF-1α promotes growth arrest and senescence in normal human cells but lacks toxic effects in transformed cells.
Luczak MW; Zhitkovich A
Toxicol Appl Pharmacol; 2017 Sep; 331():94-100. PubMed ID: 28552779
[TBL] [Abstract][Full Text] [Related]
4. Zoledronic acid inhibits thyroid cancer stemness and metastasis by repressing M2-like tumor-associated macrophages induced Wnt/β-catenin pathway.
Lv J; Chen FK; Liu C; Liu PJ; Feng ZP; Jia L; Yang ZX; Hou F; Deng ZY
Life Sci; 2020 Sep; 256():117925. PubMed ID: 32522570
[TBL] [Abstract][Full Text] [Related]
5. Mutation of isocitrate dehydrogenase 1 induces glioma cell proliferation via nuclear factor-κB activation in a hypoxia-inducible factor 1-α dependent manner.
Wang G; Sai K; Gong F; Yang Q; Chen F; Lin J
Mol Med Rep; 2014 May; 9(5):1799-805. PubMed ID: 24626950
[TBL] [Abstract][Full Text] [Related]
6. Wild-type IDH1 Knockout Leads to G0/G1 Arrest, Impairs Cancer Cell Proliferation, Altering Glycolysis, and the TCA Cycle in Colon Cancer.
Atalay EB; Senturk S; Kayali HA
Biochem Genet; 2023 Aug; 61(4):1470-1486. PubMed ID: 36633771
[TBL] [Abstract][Full Text] [Related]
7. FOXC1 induces cancer stem cell-like properties through upregulation of beta-catenin in NSCLC.
Cao S; Wang Z; Gao X; He W; Cai Y; Chen H; Xu R
J Exp Clin Cancer Res; 2018 Sep; 37(1):220. PubMed ID: 30189871
[TBL] [Abstract][Full Text] [Related]
8. Ability of Ni-containing biomedical alloys to activate monocytes and endothelial cells in vitro.
Wataha JC; Lockwood PE; Marek M; Ghazi M
J Biomed Mater Res; 1999 Jun; 45(3):251-7. PubMed ID: 10397983
[TBL] [Abstract][Full Text] [Related]
9. Mutant Isocitrate Dehydrogenase 1 Disrupts PKM2-β-Catenin-BRG1 Transcriptional Network-Driven CD47 Expression.
Gowda P; Patrick S; Singh A; Sheikh T; Sen E
Mol Cell Biol; 2018 May; 38(9):. PubMed ID: 29463646
[TBL] [Abstract][Full Text] [Related]
10. IDH1 R132H Mutation Enhances Cell Migration by Activating AKT-mTOR Signaling Pathway, but Sensitizes Cells to 5-FU Treatment as NADPH and GSH Are Reduced.
Zhu H; Zhang Y; Chen J; Qiu J; Huang K; Wu M; Xia C
PLoS One; 2017; 12(1):e0169038. PubMed ID: 28052098
[TBL] [Abstract][Full Text] [Related]
11. IDH1 Mutation Induces HIF-1
Hu X; Li L; Eid JE; Liu C; Yu J; Yue J; Trent JC
Dis Markers; 2022; 2022():7729968. PubMed ID: 35198082
[TBL] [Abstract][Full Text] [Related]
12. Isocitrate dehydrogenase 1-snail axis dysfunction significantly correlates with breast cancer prognosis and regulates cell invasion ability.
Liu WS; Chan SH; Chang HT; Li GC; Tu YT; Tseng HH; Fu TY; Chang HY; Liou HH; Ger LP; Tsai KW
Breast Cancer Res; 2018 Apr; 20(1):25. PubMed ID: 29661250
[TBL] [Abstract][Full Text] [Related]
13. Discovery of a Novel Chemical Scaffold Against Mutant Isocitrate Dehydrogenase 1 (IDH1).
Kang CH; Choi SU; Son YH; Lee HK; Jeong HG; Yun CS; Ahn S; Park CH
Anticancer Res; 2020 Sep; 40(9):4929-4935. PubMed ID: 32878781
[TBL] [Abstract][Full Text] [Related]
14. Low level of isocitrate dehydrogenase 1 predicts unfavorable postoperative outcomes in patients with clear cell renal cell carcinoma.
Laba P; Wang J; Zhang J
BMC Cancer; 2018 Aug; 18(1):852. PubMed ID: 30153799
[TBL] [Abstract][Full Text] [Related]
15. NANOGP8 is the key regulator of stemness, EMT, Wnt pathway, chemoresistance, and other malignant phenotypes in gastric cancer cells.
Ma X; Wang B; Wang X; Luo Y; Fan W
PLoS One; 2018; 13(4):e0192436. PubMed ID: 29689047
[TBL] [Abstract][Full Text] [Related]
16. Isocitrate dehydrogenase 1 mutation sensitizes intrahepatic cholangiocarcinoma to the BET inhibitor JQ1.
Fujiwara H; Tateishi K; Kato H; Nakatsuka T; Yamamoto K; Tanaka Y; Ijichi H; Takahara N; Mizuno S; Kogure H; Matsubara S; Nakai Y; Koike K
Cancer Sci; 2018 Nov; 109(11):3602-3610. PubMed ID: 30156013
[TBL] [Abstract][Full Text] [Related]
17. IDH1 mutation diminishes aggressive phenotype in glioma stem cells.
Yao Q; Cai G; Yu Q; Shen J; Gu Z; Chen J; Shi W; Shi J
Int J Oncol; 2018 Jan; 52(1):270-278. PubMed ID: 29115585
[TBL] [Abstract][Full Text] [Related]
18. IDH1 overexpression induced chemotherapy resistance and IDH1 mutation enhanced chemotherapy sensitivity in Glioma cells in vitro and in vivo.
Wang JB; Dong DF; Wang MD; Gao K
Asian Pac J Cancer Prev; 2014; 15(1):427-32. PubMed ID: 24528069
[TBL] [Abstract][Full Text] [Related]
19. IDH1-dependent α-KG regulates brown fat differentiation and function by modulating histone methylation.
Kang HS; Lee JH; Oh KJ; Lee EW; Han BS; Park KY; Suh JM; Min JK; Chi SW; Lee SC; Bae KH; Kim WK
Metabolism; 2020 Apr; 105():154173. PubMed ID: 32035087
[TBL] [Abstract][Full Text] [Related]
20. HIF-1ɑ-regulated miR-1275 maintains stem cell-like phenotypes and promotes the progression of LUAD by simultaneously activating Wnt/β-catenin and Notch signaling.
Jiang N; Zou C; Zhu Y; Luo Y; Chen L; Lei Y; Tang K; Sun Y; Zhang W; Li S; He Q; Zhou J; Chen Y; Luo J; Jiang W; Ke Z
Theranostics; 2020; 10(6):2553-2570. PubMed ID: 32194819
[No Abstract] [Full Text] [Related]
[Next] [New Search]
